To Help Blood Cells Regenerate After Radiotherapy, "Mechanoprime" MSCs

Radiation therapy to the bone marrow destroys cancerous leukemia and lymphoma cells, but it also leaves patients susceptible to infection until their blood cells can regenerate. Researchers at the Massachusetts Institute of Technology (MIT) have found a way to speed up this regeneration by using a technique known as "mechanopriming" to enhance the ability of mesenchymal stromal cells (MSCs) to aid in the process.Mesenchymal stromal cells are stem cells capable of differentiating into a variety o...
Continue reading

Duvelisib Approved for Non-Hodgkin Lymphoma Subtypes

The FDA has now granted regular approval to duvelisib (Copiktra®, Verastem, Inc.) as a third-line or later treatment for adults with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The FDA has also granted duvelisib accelerated approval as a third-line or later treatment for adults with relapsed or refractory follicular lymphoma (FL). Both CLL/SLL and FL are slow-growing types of non-Hodgkin lymphoma characterized by high rates of relapse, with limited...
Continue reading

Acute Lymphoblastic Leukemia: Immune Differences at Birth

In a new study published in Cancer Research, investigators have found neonatal inflammatory markers associated with childhood B-cell precursor acute lymphoblastic leukemia (ALL), indicating that children with ALL are born with a dysregulated immune function that may cause abnormal reactions to early childhood infections."Our findings suggest that children who develop ALL are immunologically disparate already at birth," stated lead author Signe Holst Søegaard, MSc, a PhD student in the Department...
Continue reading

Management of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors With Sara Tinsley, PhD, ARNP, AOCN

Chronic myeloid leukemia (CML) accounts for 15% of all adult leukemias and is characterized by heterogenous clinical manifestations. In recent years outcomes for patients with CML have greatly improved, in part due to the advent of tyrosine kinase inhibitor (TKI) therapy. At the Oncology Nursing Society 43rd Annual Congress in Washington, DC, i3 Health spoke with Sara Tinsley, PhD, ARNP, AOCN, from Moffitt Cancer Center, about therapeutic advances in CML and the importance of ensuring patient ad...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.